Extractables-free deep-well plate for uHPLC and MS applications
Porvair Glass Vial Deep-well plates are precisely manufactured to ensure complete compatibility with automated equipment.
The new Glass Vial Deep-well plate from Porvair Sciences is designed to ensure that absolutely no extractables or leachates are present in a withdrawn sample, thereby removing the risk of false peaks in sensitive uHPLC and MS applications.
This high-quality product combines 96 x 1-mL tapered or flat bottomed glass vials held firmly in each well of a 2-mL 96 deep-well plate. Porvair Glass Vial Deep-well plates are less costly than solid glass plates and are precisely manufactured to comply with ANSI/SLAS dimensions to ensure complete compatibility with automated equipment.
Complimented by a snug fitting silicone cap mat which seals each vial individually, with a pre-scored septum, Porvair Glass Vial Deep-well plates allow an autosampler to pierce each septum and withdraw sample from each sealed vial with high precision and reproducibility.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.